Endometrial Cancer
📧 Sign up to get email alerts when something new happens for Endometrial Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-18Clinical Trial Results: Michigan Genetic Hereditary Testing (MiGHT) [NA]
Results from the MiGHT genetic hereditary testing trial conducted at University of Michigan Rogel Cancer Center in breast, colorectal, and o…
-
CLINICAL_TRIALS trial_result · 2026-08-13Clinical Trial Results: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating NC410 plus pembrolizumab in advanced/metastatic solid tumors with various MSI statuses; terminated with posted re…
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Results: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma [Phase 2]
Phase II, single-arm trial evaluating RAD001 (everolimus) with letrozole and metformin in advanced or recurrent endometrial carcinoma; resul…
-
CLINICAL_TRIALS trial_result · 2026-07-24Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) [Phase 3]
Phase 3 trial evaluating pembrolizumab in combination with adjuvant chemotherapy with or without radiotherapy in newly diagnosed endometrial…
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer [Phase 2]
Phase 2 trial evaluating onapristone plus anastrozole for refractory hormone receptor positive endometrial cancer completed with posted resu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-07-08Clinical Trial Results: The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach [Phase 2]
Phase 2 trial results for the UPPROACH approach using upfront intensity-modulated proton beam therapy in endometrial cancer.
-
CLINICAL_TRIALS research · 2026-07-02Clinical Trial Results: Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health [NA]
Clinical trial results for adapting multiple behavior interventions to improve cancer survivor health; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) [Phase 3]
Phase 3 trial evaluating pembrolizumab with adjuvant chemotherapy, with or without radiotherapy, in newly diagnosed endometrial cancer after…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Results: Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation [Phase 2]
Phase 2 trial evaluating bevacizumab and/or niraparib in patients with recurrent endometrial or ovarian cancer harboring ARID1A mutation; st…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma [Phase 2]
Phase 2 study updating pembrolizumab with olaparib in endometrial carcinosarcoma has completed.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma [Phase 2]
Phase 2 trial evaluating cadonilimab with chemoradiation for recurrent and oligometastatic endometrial cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer [Phase 3]
Phase 3 clinical trial evaluating bevacizumab added to carboplatin and paclitaxel with pembrolizumab for advanced or recurrent endometrial c…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer [Phase 3]
Phase 3 clinical trial sponsored by BioNTech SE evaluating an unnamed investigational therapy for endometrial cancer, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) [Phase 2]
Phase 2 ComboMATCH trial evaluating neratinib alone or with palbociclib for HER2-positive solid tumors, including malignant neoplasms of the…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial [Phase 2]
Phase 2 screening trial (ComboMATCH) sponsored by the National Cancer Institute uses genetic testing to direct targeted therapies for patien…
-
EMA approval · 2026-04-23EMA Authorised: Jemperli (dostarlimab) — GlaxoSmithKline Trading Services Limited
The EMA authorised dostarlimab (Jemperli) for endometrial cancer, expanding treatment options for endometrial neoplasms.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors [Phase 2]
Phase 2 clinical trial update of ceralasertib (AZD6738) alone and in combination with olaparib or durvalumab in various solid tumors; the st…
-
CLINICAL_TRIALS withdrawal · 2026-04-23Clinical Trial Update: AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer [Phase 1, Phase 2]
A clinical trial evaluating the combination of bevacizumab and bemarituzumab for gynecologic cancers (endometrial, ovarian, and cervical) ha…
-
CLINICAL_TRIALS other · 2026-04-23Clinical Trial Update: Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma [Phase 3]
Phase 3 clinical trial update on selinexor as maintenance therapy after systemic treatment in patients with p53 wild-type, advanced or recur…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma [Phase 2]
Phase 2 study evaluating pembrolizumab plus olaparib for endometrial cancer and endometrial carcinosarcoma is currently active but not recru…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer [NA]
Clinical trial comparing proton therapy to intensity-modulated radiation therapy after surgery for cervical and endometrial cancer; the stud…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) [Phase 3]
A Phase 3 study compares sacituzumab Tirumotecan (MK-2870) in combination with pembrolizumab (MK-3475) versus pembrolizumab alone in endomet…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Laparotomy vs Laparoscopy in Endometrial Cancer Staging [NA]
A clinical trial comparing laparotomy versus laparoscopy for staging endometrial cancer, currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer (Phase 1)
This clinical trial update describes a Phase 1 study (SHAPE-ENDO) evaluating multimodal pre-surgical optimization for patients with obesity …
-
EMA approval · 2026-04-22EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, ren…